1 2	
2	Factors Related to the Utilization of Digital Adherence Technologies in
4	Tuberculosis Care: A Qualitative Study Among Adults in DS-TB Treatment,
5	Health Care Providers and Other Key Stakeholders in Tanzania
6 7	
8	Authors
9	Bianca Gonçalves Tasca <sup>1</sup> , Andrew Mganga <sup>2</sup> , Chung Lam Leung <sup>1</sup> , Lucas Shilugu <sup>2</sup> , Christopher Pell <sup>1</sup> ,
10	Baraka Onjare <sup>2</sup> , Nicholaus Luvanda <sup>2</sup> , Liza de Groot <sup>1</sup> , Kristian van Kalmthout <sup>1</sup> , Katherine Fielding <sup>3</sup> , Degu
11	Jerene <sup>1</sup>
12	
13	Affiliations
14	<sup>1</sup> KNCV Tuberculosis Foundation, the Hague, Netherlands
15	<sup>2</sup> KNCV Tuberculosis Foundation, Dar es Salaam, Tanzania
16	<sup>3</sup> TB Centre and Department of Infectious Disease Epidemiology, Faculty of Epidemiology and
17	Population Health, London School of Hygiene & Tropical Medicine, London, UK
18	
19	
20	Abstract:
21	
22	Numerous challenges, such as lengthy treatment courses, side effects, and distance to healthcare
23	facilities contribute to suboptimal Tuberculosis (TB) treatment completion. Digital adherence
24	technologies (DATs), such as smart pillboxes and medication labels, could be an alternative to
25	facilitate TB treatment continuation.
26	In-depth interviews with people undergoing treatment for drug susceptible TB, health care providers
27	(HCPs) and other key stakeholders were conducted to evaluate their experiences with DATs in ten
28	health facilities across four different regions in Tanzania. This study is part of a multi country cluster
29	randomized trials conducted under the ASCENT consortium.
30	Interviews were conducted with a total of 41 individuals, 19 people with TB and 22 HCPs and key
31	stakeholders. One of the main findings indicates that participants found that the daily reminders NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

32 provided by the DATs, particularly the alarm from the smart pillboxes, helped in supporting 33 treatment continuation and establishing a routine around medicine intake. DATs use was linked with 34 reducing the financial burden of treatment, improving people with TB-HCPs relationship, and 35 decreasing workload for HCPs. Although DATs were generally perceived as reliable, occasional 36 technical malfunctions, such as battery depletion in smart pillboxes, were reported. The requirement 37 of having access to a cellphone and a power source emerged as specific barriers for medication label 38 users. 39 This study highlights the initial willingness and sustained enthusiasm for using DATs among 40 respondents. DATs were perceived as useful tools, aiding individuals with treatment continuation 41 through daily reminders and fostering stronger connections with HCPs. Nevertheless, issues such as 42 poor network connectivity and the need for access to a working cellphone posed difficulties in 43 usage. Findings from this study suggest the potential for improvements in the technologies and 44 indicate that a thorough assessment of people's life conditions and needs prior to treatment 45 initiations is important to determine the suitability of providing a DAT. 46

## 47 Introduction

48 Tuberculosis (TB) continues to be a major global public health challenge, affecting an
49 estimated 10.6 million individuals worldwide and resulting in 1.3 million deaths in 2022 [1], despite
50 being preventable and curable. Identifying and promptly treating individuals affected by TB and
51 ensuring they have optimal conditions to complete the treatment has the potential to save millions
52 of lives and eliminate the transmission of TB [2].

53 With around half the people with TB in the 30 high-burden countries successfully completing 54 their treatment, there are concerning gaps in the TB care cascade [3]. Lengthy treatment duration 55 and potential side effects are known to contribute to treatment discontinuation [4]. Other factors, 56 such as forgetting to take medication, lack of knowledge about the importance of completing the

treatment, drug stockouts, distance to the healthcare facility and stigma, also negatively impact
treatment continuation [5,6].

59	Directly observed therapy (DOT) has been the standard recommendation to enhance
60	completion in TB treatment [7]. However, implementing strict DOT has posed challenges over the
61	years. Frequent visits to clinics increased the workload for healthcare providers (HCPs) and created
62	barriers for individuals on treatment due to extra costs associated with frequent travel [8]. In light of
63	these challenges, digital adherence technologies (DATs) have emerged as possible alternatives to
64	enhance TB treatment completion and improve outcomes. Recognizing the potential of digital
65	solutions, the World Health Organization (WHO) issued recommendations regarding the
66	implementation of DATs as part of integrated patient care [9].
67	DATs, such as cellphone-based reminders and smart pillboxes, have demonstrated the
68	potential to enhance treatment initiation and completion in TB care [4]. A prior study conducted in
69	Tanzania, involving people living with TB and HCPs utilizing medication labels (99 DOTs) for
70	treatment support, revealed that HCPs believed the technology aided them in delivering better
71	treatment, while people living with TB concurred that it facilitated their treatment continuation [10].
72	However, more in-depth information regarding user-related factors and the usage of DATs in TB
73	treatment is needed to strengthen the evidence base.
74	For DATs to be effective, they must accommodate the needs and preferences of both people
75	with TB and HCPs. In order to understand the factors that influence experiences with using and
76	implementing medication labels, smart pillboxes and the EverWell adherence platform, we
77	conducted in depth interviews with people living with drug susceptible TB (DS-TB), HCPs and other
78	key stakeholders in Tanzania. This qualitative study is part of a multi-country, cluster-randomized
79	trials, the Adherence Support Coalition to End TB (ASCENT) consortium [11].
80	

# 81 Methods

## 82 Study Setting

83 The ASCENT cluster randomized trials were conducted in Ethiopia, Tanzania, The Philippines, 84 South Africa, and Ukraine. Two separate randomization processes occurred prior to the commencement of the study. Firstly, health facilities were randomized to either the intervention or 85 the standard of care arm. A second randomization process determined the type of DAT provided at 86 87 each intervention arm facility. People with TB enrolled in the intervention arm were offered either a 88 smart pillbox or medication labels, depending on the health facility they received care from. If a 89 person didn't have access to a cellphone in a health facility that provided medication labels, then a 90 smart pillbox would be offered as an alternative solution. HCPs used the EverWell adherence 91 platform to monitor DATs engagement, a proxy for adherence to treatment regimens. 92 Smart pillboxes are devices for storing TB medications. They provide users with audio-visual 93 reminders and maintain a record of each instance the box is opened, transmitting this dosing history 94 to the adherence platform. Conversely, medication labels consist of blisters packs with printed 95 codes. These codes are used by people with TB to report their medication intake via toll-free SMS 96 texts. In the event that a person living with TB fails to open the box or sends an SMS text - proxies of 97 medication intake - an automatic message is dispatched to their cellphone (or cellphone they have access to) as a reminder to take their prescribed medicine. 98 99 For HCPs, the adherence platform offered daily adherence data accessible through a webbased dashboard or smartphone app. In cases where people with TB were observed to have missed

based dashboard or smartphone app. In cases where people with TB were observed to have missed
their medication, HCPs were instructed to initiate a differentiated care approach, including home
visits to individuals who had missed their doses for three consecutive days. Prior to the start of the
intervention, healthcare workers received training on the proper use of DATs and the adherence
platform. Training was provided once for two days at the beginning of the project for all HCPs.
ASCENT staff also provided monthly technical support on demand throughout the trial
implementation period, including quarterly supportive supervision.

107 In Tanzania, DATs were implemented in 36 health facilities [11] as part of the ASCENT

108 intervention. With an estimated population of 58 million in 2019 [12], the country is among the 109 three high TB burden countries that reached or surpassed the initial milestones of the End TB 110 Strategy for reducing both TB incidence and deaths by 2019. Tanzania, however, is still categorized as a high-burden country for TB and HIV-associated TB [13]. Studies conducted in the country have 111 shown suboptimal treatment completion rates, with only 79% of people with TB achieving 95% 112 113 adherence levels in the Kilimanjaro region [9]. 114 TB treatment in Tanzania is administered through the primary healthcare network under the 115 guidance of the National TB Programme. The treatment approach emphasizes patient-centered care, 116 with a predominance of self-administered and home-based treatment modalities. The provision of 117 free TB care in Tanzania aims to ensure universal access to treatment and mitigate the 118 socioeconomic burden associated with the disease [12]. 119 120 **Study Population** 121 In this qualitative evaluation, the study population encompassed people with TB using DATs 122 for their DS-TB treatment at ASCENT facilities, HCPs, and other key stakeholders, from the four study 123 regions in Tanzania: Arusha, Geita, Manyara and Mwanza. Interviews were conducted in 10 randomly selected facilities, ensuring diverse representation based on the type of DAT used. 124 125 Recruitment of people with TB occurred between April 1st, 2022, and July 30th, 2022. HCPs and 126 other key stakeholders were recruited from January 22nd, 2023, to March 31st of the same year. 127 Participants were invited to join the study via phone calls, with people with TB contacted by HCPs, 128 and HCPs and other key stakeholders contacted by ASCENT staff. All interviews were conducted by 129 ASCENT staff. Eligibility criteria for people with TB included being at least 18 years old and receiving drug-130 susceptible TB (DS-TB) treatment using a DAT for a minimum of one month. Exclusion criteria 131 encompassed individuals diagnosed with multi-drug-resistant TB (MDR-TB). HCPs were invited to 132 133 participate in the interviews if they were over 18 years old and held positions as clinical officers,

134 nurses, or community health workers at one of the thirty-six health facilities involved in the

135 intervention arm. Additionally, professionals from the Ministry of Health/National TB program and

136 ASCENT research staff were also invited to partake in the interviews.

137 Data collection

An initial sample size of twenty people living with TB and twenty HCPs and other key

139 stakeholders was established. Interviews were conducted until research interviewers perceived data

saturation. In-depth interviews with people with TB took place during their routine visits to health

141 facilities, where a private and quiet space was allocated for the interviews. Key stakeholders and

142 HCPs interviews were prearranged and conducted in private office spaces to maintain

143 confidentiality. The interviews followed an interview guide of open questions drawn from key

144 themes and used in a flexible manner to capture each participant's unique experiences. Among

145 individuals living with TB, interviews explored topics such as, participants' social relations, barriers

and facilitators to treatment completion, technology literacy, and their understanding and appraisal

147 of the DATs. Interviews were conducted from February to September 2022.

Within the group of key stakeholders and HCPs, interviews explored their experiences in delivering TB treatment through DATs, using the adherence platform, implementing differentiated responses, and their perspectives on the feasibility of integrating DATs within the differentiated model of care. Interviews were conducted in Kiswahili and audio recorded using portable sound recorders. Interviewers, AM, LS and NL were experienced in conducting qualitative interviews with TB/HIV clients. They had received post-graduate training in research methods and were oriented on the use of the interview guide.

155

## 156 Data processing and analysis

157 Interviews recordings were transcribed verbatim and subsequently translated into English by 158 AM and LS. The analysis process was undertaken by three additional researchers, BT, LG and AL, with 159 regular discussions with AM and DJ. Initially, all interview transcripts were thoroughly read by both

160 researchers to gain familiarity with the content. Subsequently, relevant codes were developed, 161 taking in consideration the study's objectives. Once patterns in the data were identified, themes 162 were defined, and thematic analysis sessions were conducted to achieve a final consensus on the relevant themes. The selection of themes was based on their thematic relevance to the research aim 163 [14]. The data were analyzed using NVivo 12 qualitative analysis software and Microsoft Excel. 164 165 For this study, a practical thematic analysis approach was adopted, employing a hybrid 166 analysis [15]. This approach entailed the utilization of both inductive and deductive methods, along 167 with semantic and latent thematic analysis techniques, to develop the codes and derive meaningful 168 insights from the data. 169 170 **Ethical Approval** 171 Ethical approval to the study was obtained from the World Health Organization (WHO) Ethics Review 172 Committee, the London School of Hygiene & Tropical Medicine (LSHTM), and Tanzania's National 173 Institute for Medical Research (NIMR) as a sub study under the overall ASCENT protocol. Prior to 174 participation, written informed consent was obtained from all participants, and the sessions were 175 audio recorded for transcription purposes. 176 Results 177

Of the 41 respondents interviewed, 19 were people with TB, and 22 were HCPs and other key stakeholders. Among people with TB, five were using medication labels and 14 were using the smart pillbox at the time of the interview. One of the participants using the smart pillbox had transitioned from the medication label during the trial due to cellphone damage. Among the people with TB who were interviewed, 11 (58%) were males and eight (42%) were between 30-39 years of age. In three instances people with TB were interviewed alongside their caregivers. This approach was adopted to address language barriers and/or assist elderly participants.

- 185 Key stakeholders and HCPs who took part in the research comprised community health
- 186 workers, nurses, district TB and Leprosy coordinators and ASCENT research staff. Key stakeholders
- and HCPs participating in the study had a diverse range of years of experience in their respective
- 188 roles, going from 1 to 14 years. Table 1 shows the characteristics of the interviewees.

189

190

## 191 Table 1: People with TB, HCPs and key stakeholders' demographic characteristics

People with TB		N (%)	)	
DAT type used at the moment of the interview				
Smart Pillbox	Smart Pillbox			
Medication Label		5 (26%	6)	
Sex				
Male		11 (58%)		
Female		8 (42%)		
Age range (years)				
18-29		2 (11%	6)	
30-39	30-39		8 (42%)	
40-49		5 (26%)		
50-59		0 (0)		
≥60		4 (21%)		
Total		19		
Key stakeholders and HCPs		N (%)		
Community health Worker		4 (18%)		
Nurse		8 (36%)		
District TB and Leprosy coordinator		3 (14%)		
ASCENT Research Staff		1 (5%)		
Regional TB and Leprosy coordinator		4 (18%)		
Regional TB and HIV officer		2 (9%)		
Total		22 (100%)		
	Min.	Mean	Max.	
HCPs and other key stakeholders years of experience	1	5	14	

- 192
- 193

In the context of the ASCENT intervention, nurses reported handling tasks such as enrolling
people with TB in the adherence platform, and initiating them on treatment, whereas community
health workers focused on treatment follow-up and home visits. Other key stakeholders, including

the Regional TB and Leprosy Coordinator, Regional TB and HIV Officer, and District TB and Leprosy

198	Coordinator, described their main activities as ensuring DATs availability, organizing technical
199	support, and providing oversight in ASCENT facilities. Meanwhile, ASCENT research staff managed
200	routine activities like supportive supervision, monitoring treatment continuation via the EverWell
201	adherence platform, communication with service providers, data collection for project studies, and
202	offered technical support for the EverWell and DATs utilization.
203	
204	Overall engagement with DATs
205	People with TB and HCPs demonstrated an initial inclination to engage with the DATs.
206	Amongst respondents, it was widely reported that the technologies could make one's life easier and
207	participants were willing to try the DATs. In the HCPs interviews, respondents described feeling a
208	renewed motivation to work once they heard about the implementation of the DATs. The
209	interviewed HCPs also reported a high rate of technology uptake among people with TB. People with
210	TB described a willingness to adhere to treatment and seemed to understand the importance of
211	concluding the full treatment course.
212	
213	"When patients come for starting TB treatment, they ask I hear there is this smart pillbox, I would
214	love to have it for helping me with my medication." (Nurse, #3516)
215	
216	The ASCENT research team was responsible for training HCPs who subsequently instructed
217	people with TB on using the DATs. HCPs indicated that these orientation sessions varied from fifteen
218	minutes to two hours, depending on individual needs. Generally, nurses assumed the responsibility
219	of conducting these instruction sessions.
220	People with TB said that they were satisfied with the instructions received. Participants
221	recounted how adapting and incorporating the DATs into their daily routines was easy. Both
222	technologies were referred to as user-friendly, demanding minimal effort. Frequently, they had
223	acquaintances with prior experience of using DATs, which not only helped them better comprehend

"It was easy for me to understand because one of my friends had already used the technology before

the technology but also provided support in effectively using DATs.

225

226

227	and he had explained the details to me; it helped me to be more accepting of using the technology.
228	So, I understood the health provider very easily." (Person with TB using medication labels, Male, Age:
229	30-39 years, #1908)
230	"There is no challenge at all. It is easy to open, take the pills and close it. [There are] even no
231	difficulties in storing it ." (Person with TB using a Smart Pillbox, Female, Age: 40-49 years, #2374)
232	
233	The perceived utility of DATs
234	Daily reminders and treatment routine
235	People with TB emphasized that the alarm notifications and messages helped with
236	treatment continuation, averting missed doses. The daily reminders helped them create a structured
237	routine for medicine intake. People with TB said that just by seeing the smart pillbox they would
238	already remember to take the medicine. Similar feelings were shared when respondents considered
239	the viewpoint of their family members. They recounted how their relatives got involved in the
240	treatment process by reminding them to take their medicine whenever they saw the box or heard its
241	alarm.
242	
243	"Even myself by observing the box (smart pillbox) around, even if it is not yet time for taking the
244	medication, I will remember that this box reminds me to take medication when it reaches a particular

245 *time"* (Person with TB using a Smart Pillbox , Female, Age: 40-49 years, #1535 )

246

Nonetheless, some people with TB expressed a desire to have the flexibility to change the alarm volume for the smart pillboxes because there were instances when they could not hear the alarm sounding. Participants using medication labels did not benefit from alarms and healthcare

workers mentioned that people using this technology would occasionally forget to send SMS
notifications despite having taken their medication.

252

253 "Mainly there are challenges with the 99 DOTS [medication labels], some [people with TB] most of
254 the time they forget to send SMS, but they may have taken the medicines already." (District TB and
255 Leprosy coordinator, #3819)

256

HCPs and other key stakeholders also pointed out that by engaging with a DAT, people with
TB would become aware of the importance of staying on treatment and creating a routine around it.
HCPs identified the adherence platform as another attribute of the DATs that helped people with TB
in continuing the treatment because it helped prompt an action from their side and prevent people
living with TB being lost to follow up.

263 *"The other benefit is that patients were not missing doses or dropping [out] from treatment, because*264 *we could easily notice that within a day or two and trace them to get the patient back [on their*

265 treatment]." (Community Health Worker, #3314)

266

267 *"TB treatment takes six months. If taking medicine for a week tends to be a challenge, six months is a*268 *marathon. But through smart pillboxes, which remind patients when to take medication, the patients*269 *have been able to take their medicines daily and complete their treatment on time. And, in some*270 *cases, it does not only remind them to take their medication, but also in other activities, like waking*271 *up kids for schools, time to wake up for farming and milking the cattle." (ASCENT project staff,*272 #3011)
273
274 Smart pillboxes as medicine storage devices

275 Participants from all groups highlighted that the smart pillboxes are a useful storage device

- 276 for keeping medicine safe and away from dust and dirt. Nonetheless, some people with TB
- 277 highlighted that the standardized features of the smart pillboxes did not consistently match their
- individual requirements. Some criticized the box for its compact size.
- 279
- 280 "It [smart pillbox] enables me to store my medicine. (...) I could have been storing medicine using
- 281 papers/magazine which is not very safe as the medicine could get dirty at times."
- 282 (Person with TB using a smart pillbox, Female, Age: ≥60 years, #2495)
- 283
- 284 Cost-saving and reduced travels with DATs
- 285 Another perceived benefit arising from DAT utilization was the potential for cost savings.
- 286 When individuals were using a DAT, they were only required to visit the health facility once a month
- to refill their medication, thereby reducing the necessity of additional trips to ensure medication
- 288 intake. This also allowed people with TB to maintain their normal routine and provided them with
- additional time to rest, if needed. Key stakeholders highlighted the importance of such an aspect for
- 290 people living in remote areas and said this was an indication of how DATs could adapt well to
- 291 different contexts.
- 292
- 293 *"It reduces the hustle of constantly coming to the health facility just for the [DOT provider] to see if*
- 294 you have really taken the medicine and saves travel costs to the health facility." (Person with TB
- using Medication label, Male, Age: ≥60 years, #1498)
- 296 *"Among the benefits it has reduced financial costs for patients to visit facilities regularly particularly*
- 297 those residing at far places" (Nurse, #4122)

298

299 Managing care for the many

300	According to HCPs and key stakeholders, the utilization of the adherence platform made the
301	process of supporting treatment easier. HCPs reported being able to assess in a timely manner a
302	large number of peoples' treatment continuity patterns. This alleviated their workload because they
303	did not need to rely on previously time-consuming strategies, such as counting empty blisters, to
304	assure users were taking medication as expected. They felt as if the workload had diminished
305	because they could perform tasks faster. Work also became more efficient because they could focus
306	their efforts on people that showed suboptimal treatment continuation on the platform and prompt
307	the initiation of a differentiated response based on the adherence platform information.
308	
309	"This new [adherence platform] has simplified our work. For instance, when you enter the office in
310	the morning, you look on the tablet to monitor adherence of the patients on treatment, we follow up
311	on patients with bad adherence who can say that they experience network challenges or maybe they
312	forgot on that day, or s/he has been hospitalized on that day, so ASCENT has been so useful on
313	monitoring patients for us." (Nurse, #4122)
314	
315	Cellphone-related challenges and the use of medication labels
316	The requirement of access to a cellphone prevented the widespread provision of the
317	medication labels to people living with TB in Tanzania. It was not uncommon for people to share
318	cellphones, lose the device during treatment, or change numbers. These factors, together with the
319	need for access to a power source to charge the cellphone, made it challenging for people with TB to
320	effectively engage with the medication labels.
321	
322	"The challenge is with charging the phone; some days it happens the phone has no power and has to
323	be charged. As a result, you take the pills without sending the massage." (Person with TB using

- 324 medication label, Male, Age: 40-49 years, #1498)
- 325 *"The challenges are with {medication] labels because of using cellphone, you may find a client has*

lost their cellphone, and when they change for another SIM card, they won't tell you until you start
follow up." (Nurse, #3516)

328

## 329 Technical issues and DATs

330 Overall both technologies were described as generally reliable but not without technical 331 malfunctions. People with TB on both the smart pillboxes and medication labels said that sometimes 332 they would receive a reminder message even after opening the box/sending a message, leading to 333 confusion. Other technical challenges specifically related to the smart pillboxes were the fact that 334 the alarm would ring at incorrect times and battery depletion, which required people to go to the 335 facility for charging. HCPs noted that people with TB often became concerned when encountering 336 errors in the DATs. In response, during the instruction sessions, they began explaining that technical 337 malfunctions could happen, to alert and reassure users. The adherence platform also presented 338 errors from time to time, occasionally taking a long time to update medication intake information. 339

"I got confused and I had to contact the nurse, the nurse said that I had to continue sending
[confirmatory messages] to the number. I continued... most times I would get a message back [from
the platform] other times I would get a message reminding me to take my medication in the
evening." (Person with TB using Medication label, Male, Age: ≥60 years, #1806)
"Some days the adherence platform could not be accessible. This happens every now and then, so
you may find red marks to all patient calendar as if patients have not taken their medicines while
they did swallow because when we call them, they will say I did swallow the pills." (Nurse, #2506)

348 Some people with TB faced intermittent network connection, which prevented them from 349 being able to send or receive messages in a timely manner. HCPs described that such issues also 350 affected users on smart pillboxes when the box could not synch with the platform until the person 351 arrived in an area with network connection. This would make people with TB worry, and some

- 352 mentioned going to the health facility to seek guidance or even sending several messages in a day to
- assa ensure their medication intake was accurately recorded.
- 354
- 355 *"The other challenge is poor network on some days, which led to the message to fail to be delivered.*
- 356 It appears like you did not take the medicine, whereas in fact you did take it, but due to poor network
- 357 the short text code could not be successfully sent." (Person with TB using Medication label, Male,
- 358 Age: 40-49 years, #2014)
- 359

## 360 Social and interpersonal aspects of using DATs

## 361 Enhanced people with TB-HCPs relationship

362 Among the perceived benefits of using DATs, people with TB described feeling connected to

363 HCPs facilitated by these technologies. They perceived HCPs as closer to them and found an added

364 value in terms of understanding that DATs facilitate HCPs tasks by automatically reporting their

365 medicine intake history.

366

367 *"The pill box has been helpful for quickly sending information to the nurse that I have taken* 

368 medication on that day. Just after opening the box the nurse will get to know I have taken the pills."

369 (Person with TB using Medication label, Male, Age: 30-39 years, #2301)

370 *"Using this technology helps simplify communication with the clinic. I get to inform the nurse every* 

371 *day I take the pills, I see like I am together with the nurse.*" (Person with TB using Medication label,

372 Male, Age: ≥60 years, #2014)

373

374 HCPs echoed this impression, highlighting the positive impact on their relationship with 375 people with TB. They phrased this in terms of building greater trust and collaboration with people 376 with TB. Even though the information on the adherence platform can only be seen as a proxy for 377 medication intake, they perceived that they could trust that people were properly taking the

378	medication. Also, they described how people with TB could also have more trust in HCPs because
379	they would be able to act quicker if they realized a person was not utilizing the technology.
380	
381	"The intervention has made us work together with the patients unlike in the past when we just
382	provided the medicines to the patient and let them go until they return for refill in a week or two.
383	Even if they experienced challenges/side effects on taking their pills it was difficult to know. So, I see
384	the patients feel as if they are valued and closely cared for. When we follow up and ask them about
385	their progress, they say thanks for caring about my health, thanks for calling to ask about my
386	condition. So, this intervention has given us a close and friendly relationship with our patients".
387	(Nurse, #2203)
388	
389	Social networks as influencers in DATs usage
390	People with TB described receiving encouragement to start using the DATs and continue
391	their treatment. Some individuals mentioned familiarity with both the treatment and the DATs
392	through friends and family previous experiences, which made it easier to understand and utilize the
393	technology. People with TB themselves expressed a willingness to encourage other people to engage
394	with the DATs.
395	
396	"Interviewer: So, disclosing using a DAT was not a problem to you?
397	Person with TB: No, the thing is once you start using that thing, you will convince other people to use
398	it because it's sweet." (Person with TB using Smart Pillbox, Male, Age: 40-49 years, #1663)
399	
400	HCPs noted that some people with TB had concerns about being seen with the smart
401	pillboxes. This feeling appears to be particularly true among younger people who may feel 'shy'
402	about carrying the devices. Additionally, HCPs have reported that people using the medication labels

403 may have concerns that others could access their cellphone messages and discover that they are404 undergoing TB treatment.

405

406 "Some of the youth we registered to use pill boxes were worried on how to carry the pill box when they
407 want to travel to somewhere else, unlike the elders who are just comfortable, the youth feel a bit shy
408 or like how will people see me if I carry this pill box." (Nurse, #2304)

## 409 Cultural traditions and the reutilization of DATs

410 Cultural traditions were raised as a potential obstacle for the reuse of smart pillboxes. In 411 Tanzania, there exists a custom of burying individuals along with their possessions, and this has 412 raised apprehensions among key stakeholders about the feasibility of re-using the DATs, even 413 though there seemed to be limited instances of such occurrence.

414

415 "There is also an understanding challenge: you may tell a patient that this smart pillbox given to you 416 will need to go to another patient after you are done with treatment and the treatment supporters 417 may be present hearing that, but if that patient dies... in some society's tradition, particularly some 418 of our fellow Sukuma believe that when a patient dies, s/he should be buried with all of her/his 419 treatment equipment, so these are among the challenges with DAT." (ASCENT project staff, #3011)

420

428

#### 421 Discussion

Tuberculosis treatment is a lengthy process that can pose numerous challenges, such as adverse reactions, which can lead to treatment interruptions [16]. DATs were designed to provide an additional layer of support, aiding individuals to follow their treatment regimen. The objective of the present study was to evaluate the firsthand experiences of individuals living with TB, HCPs and other key stakeholders within the Tanzanian healthcare system, regarding the utilization of DATs: the medication labels and the smart pillboxes alongside the adherence platform utilized by HCPs.

The findings indicate an initial willingness among participants to utilize DATs. HCPs indicated

429 a high acceptance among people with TB for utilizing DATs as part of their treatment, HCPs 430 themselves were motivated to integrate these technologies into their daily work routines. This 431 attitude appeared to persist even after participants experienced the technologies, as evidenced by people with TB predisposition of recommending DATs to others. This indicates an acceptance of the 432 studied DATs, which aligns with findings from other studies conducted in Uganda and Tanzania, 433 434 where the 99DOTS technology (medication label) was found to be highly acceptable among people 435 with TB, HCPs, and TB officers [10,17]. Additionally, the smart pillboxes were also found to be 436 associated with high degrees of satisfaction and acceptability among people with TB and healthcare 437 workers in China [18].

During the interviews, engaging with DATs was generally seen as straightforward and requiring minimal effort. Training sessions seem to have had an important role in shaping this impression. Previous studies have also highlighted the need for training and follow-up advice sessions for appropriate engagement with the DATs, whereby sufficient orientation for HCPs, people with TB and their families was a necessary condition for appropriate technology engagement [17,19,20].

444 One of the standout advantages offered by DATs was their ability to prompt medication reminders, a feature associated with enhanced adherence, as recounted by people with TB and 445 446 HCPs. DATs accomplish this through functionalities such as the alarm and messaging systems, 447 engaging not just people with TB but also involving caregivers and family members as seen in the 448 interviews. This benefit was mostly perceived by users of the smart pillboxes. The adherence 449 platform was also seen as an important factor influencing treatment continuation because HCPs 450 were able to target their actions to people with suboptimal treatment continuation. Similar findings 451 were reported in a study conducted in India, where people with TB appreciated that smart pillbox 452 reminders helped them maintain treatment consistency and avoid missing doses [20]. 453 In the current study, participants reported a reduction in financial burden due to the DATs.

This was linked to reduced journeys to the healthcare facilities and the ability to continue their

454

455 regular daily activities. This is consistent with findings from prior studies in which HCPs highlighted 456 that people with TB, especially from rural areas who usually must travel long distances to reach a 457 health unit, benefited from less frequent travelling [19,20]. This observation underscores the potential contribution of these technologies towards fulfilling a key objective of the End TB Strategy, 458 459 which seeks to prevent individuals from incurring catastrophic costs related to TB [21]. 460 The HCPs perception that DATs improved their work by enabling easy monitoring of individual's' medication intake and diminishing workload is another important perceived benefit of 461 the DATs. In a previous study conducted in Tanzania, HCPs also reported a decrease in workload 462 463 which enabled them to spend more quality time engaging with people with TB [10,19]. 464 Network issues, along with the need for a cellphone and access to electricity, posed a 465 significant barrier for the uptake of the medication label. Such an issue was already reported as an 466 important limitation of this technology and although in the present study it was not possible to 467 assess differences between area of living and socioeconomic strata, studies indicate that people 468 living in rural areas and of low socio-economic levels might be the most affected by these issues 469 [17,20]. 470 In this study, DATs were seen as having the capacity to improve the relationship and 471 collaboration between people living with TB and HCPs. People with TB have said to feel more 472 connected to the HCPs and HCPs expressed feeling a greater sense of collaboration with patients. 473 This was also reported in different studies where DATs appear to have contributed to the cultivation 474 of mutual trust and care between individuals with TB and HCPs [10,17,22]. 475 A small number of individuals with TB interviewed mentioned being reluctant to disclose 476 their TB status or the usage of DATs. However, HCPs noted that younger participants expressed

477 apprehension about using smart pillboxes due to concerns about potential stigmatization. This

478 finding aligns with a study conducted in South Africa, where HCPs reported that people with TB

479 struggled to keep their TB status concealed when using smart pillboxes. As a result, these individuals

480 often left the devices behind when they needed to travel or go to work [20,24].

481 Cultural traditions were viewed as a potential obstacle to the reuse of DATs. Key
482 stakeholders commonly believed that burial customs could be an obstacle to the sustainability of
483 DATs implementation even though there was only one occurrence reported. Nevertheless,
484 conducting further investigation and providing specific guidance on this matter could be a valuable
485 initiative in this context.

## 486 Strengths and limitations

The study is limited by the fact that participants were recruited through convenience sampling from health facilities, which meant that the perspectives of individuals that discontinued using DATs or were lost to follow up were not included. We can only partially grasp the impressions of the people with TB who experienced difficulties with their treatment regimen or with the DATs through the information that HCPs and key stakeholders provided. This also prevented us from gaining further insight into the differentiated response because only individuals with suboptimal treatment continuation would receive such care.

Two key strengths of the study are the diversity of roles held by the interviewed key stakeholders, which ensured a wide range of opinions, and the inclusion of participants from the four regions of the trial, enhancing the study's representativeness within the Tanzanian context.

497

## 498 Conclusions

This study aimed to provide insights into the use of medication labels, smart pillboxes and the EverWell adherence platform, for TB treatment in Tanzania among people with TB, HCPs and other key stakeholders. Interviews suggest that respondents showed an initial willingness to accept the technologies, which was sustained after experiencing the tools.

The study findings underscore that DATs were seen as useful by participants but that the technologies' suitability is dependent on a person's life conditions and preferences. Factors such as owning a cellphone, access to reliable network and electricity, age, and socioeconomic status appear to influence the extent to which a person can benefit from these technologies.

507		To establish a more patient-centric approach to care, the decision regarding which DAT to	
508	use and whether to employ one should be thoroughly discussed and evaluated in consultation with		
509	the person initiating TB treatment. Further research, stratified by socioeconomic strata, could		
510	provide more insights into how well-suited these technologies are for benefiting those who are most		
511	in need.		
512			
513 514 515 516 517 518	Acknowledgments The authors would like to thank all study participants for their valuable contributions.		
518	Refer	ences	
520	1.	Global tuberculosis report 2023. Geneva: World Health Organization; 2023.	
521 522 523	2.	Ryckman T, Robsky K, Cilloni L, Zawedde-Muyanja S, Ananthakrishnan R, Kendall EA, et al. Ending tuberculosis in a post-COVID-19 world: a person-centred, equity-oriented approach. Vol. 23, The Lancet Infectious Diseases. Elsevier Ltd; 2023. p. e59–66.	
524 525 526	3.	Kim J, Keshavjee S, Atun R. Health systems performance in managing tuberculosis: Analysis of tuberculosis care cascades among high-burden and non-high burden countries. J Glob Health. 2019;9(1).	
527 528	4.	Zaidi HA, Wells CD. Digital health technologies and adherence to tuberculosis treatment. Vol. 99, Bulletin of the World Health Organization. World Health Organization; 2021. p. 323-323A.	
529 530 531 532	5.	Msoka EF, Orina F, Sanga ES, Miheso B, Mwanyonga S, Meme H, et al. Qualitative assessment of the impact of socioeconomic and cultural barriers on uptake and utilisation of tuberculosis diagnostic and treatment tools in East Africa: A cross-sectional study. BMJ Open. 2021 Jul 12;11(7).	
533 534 535	6.	Tesfahuneygn G, Medhin G, Legesse M. Adherence to Anti-tuberculosis treatment and treatment outcomes among tuberculosis patients in Alamata District, northeast Ethiopia. BMC Res Notes. 2015 Sep 29;8(1).	
536 537	7.	Bayer R, Wilkinson D. Directly observed therapy for tuberculosis: history of an idea. The Lancet. 1995 Jun 17;345:1545–8.	
538 539	8.	Sagbakken M, Frich JC, Bjune GA, Porter JDH. Ethical aspects of directly observed treatment for tuberculosis: a cross-cultural comparison. BMC Med Ethics. 2013;14:25.	
540 541 542	9.	Sumari-De Boer M, Pima FM, Ngowi KM, Chelangwa GM, Mtesha BA, Minja LM, et al. Implementation and effectiveness of evriMED with short messages service (SMS) reminders and tailored feedback compared to standard care on adherence to treatment among	

543tuberculosis patients in Kilimanjaro, Tanzania: Proposal for a cluster randomized controlled544trial. Trials. 2019 Jul 12;20(1).

- Efo E, Onjare B, Shilugu L, Levy J. Acceptability, Feasibility and Accuracy of 99DOTS Adherence
   Technology in Mining Region of Tanzania. In: Cunningham M, Cunningham P, editors.
   Acceptability, Feasibility and Accuracy of 99DOTS Adherence Technology in Mining Region of
   Tanzania . 2021. p. 1–12.
- Jerene D, Levy J, Van Kalmthout K, Rest J Van, McQuaid CF, Quaife M, et al. Effectiveness of
   digital adherence technologies in improving tuberculosis treatment outcomes in four
   countries: a pragmatic cluster randomised trial protocol. BMJ Open. 2023 Mar 14;13(3).
- 552 12. Kilale AM, Pantoja A, Jani B, Range N, Ngowi BJ, Makasi C, et al. Economic burden of
  553 tuberculosis in Tanzania: a national survey of costs faced by tuberculosis-affected
  554 households. BMC Public Health. 2022 Dec 1;22(1).
- 555 13. Global tuberculosis report 2022. Geneva: World Health organization; 2022.
- 556 14. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101.
- 557 15. Saunders CH, Sierpe A, Von Plessen C, Kennedy AM, Leviton LC, Bernstein SL, et al. Practical
  558 thematic analysis: a guide for multidisciplinary health services research teams engaging in
  559 qualitative analysis. BMJ. 2023;
- 16. Handbook for the use of digital technologies to support tuberculosis medication
  adherence. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO
- Leddy A, Ggita J, Berger CA, Kityamuwesi A, Sanyu AN, Tinka LK, et al. Barriers and Facilitators
   to Implementing a Digital Adherence Technology for Tuberculosis Treatment Supervision in
   Uganda: Qualitative Study. J Med Internet Res. 2023;25.
- 56518.Liu X, Blaschke T, Thomas B, De Geest S, Jiang S, Gao Y, et al. Usability of a medication event566reminder monitor system (MERM) by providers and patients to improve adherence in the567management of tuberculosis. Int J Environ Res Public Health. 2017 Sep 25;14(10).
- Guzman K, Crowder R, Leddy A, Maraba N, Jennings L, Ahmed S, et al. Acceptability and
   feasibility of digital adherence technologies for drug-susceptible tuberculosis treatment
   supervision: A meta-analysis of implementation feedback. PLOS Digital Health. 2023 Aug
   15;2(8):e0000322.
- 572 20. Thomas BE, Kumar JV, Periyasamy M, Khandewale AS, Mercy JH, Raj EM, et al. Acceptability
  573 of the medication event reminder monitor for promoting adherence to multidrug-resistant
  574 tuberculosis therapy in two indian cities: Qualitative study of patients and health care
  575 providers. J Med Internet Res. 2021 Jun 1;23(6).
- 576 21. Mcquaid CF, Foster N, Quaife M, Levy J, Tadesse AW, Charalambous S, et al. Digital adherence
  577 technology for TB: Focus on livelihoods as well as lives. Vol. 25, International Journal of
  578 Tuberculosis and Lung Disease. International Union Against Tuberculosis and Lung Disease;
  579 2021. p. 416–7.
- Thomas BE, Vignesh Kumar J, Onongaya C, Bhatt SN, Galivanche A, Periyasamy M, et al.
  Explaining differences in the acceptability of 99DOTS, a cell phone-based strategy for
  monitoring adherence to tuberculosis medications: Qualitative study of patients and health
  care providers. JMIR Mhealth Uhealth. 2020;8(7).

- Iribarren SJ, Sward KA, Beck SL, Pearce PF, Thurston D, Chirico C. Qualitative evaluation of a
  text messaging intervention to support patients with active tuberculosis: Implementation
  considerations. JMIR Mhealth Uhealth. 2015 Mar 1;3(1).
- 587 24. Mukora R, Maraba N, Orrell C, Jennings L, Naidoo P, Mbatha MT, et al. Qualitative study
  588 exploring the feasibility of using medication monitors and a differentiated care approach to
  589 support adherence among people receiving TB treatment in South Africa. BMJ Open. 2023
  590 Mar 3;13(3).